| Abstrakt: |
A recent study conducted at Virginia Polytechnic Institute and State University (Virginia Tech) has explored the development of vaccines for the Chikungunya virus. Chikungunya virus is a significant human pathogen that causes severe febrile illness and chronic joint pain. The researchers utilized a chimeric infectious clone of the virus to express two antiviral and immunomodulatory cytokines, IFNg and IL-21, in order to enhance the vaccine's attenuation while maintaining its immunogenicity. The vaccine candidates showed promising results, providing complete protection to mice challenged with the wild-type virus. This innovative approach could potentially be applied to other viruses as well. [Extracted from the article] |
